about
Management of trypanosomiasis and leishmaniasisUse-dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersCarbohydrate-related inhibitors of dengue virus entrySmall Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture MechanismThe Trypanocidal Drug Suramin and Other Trypan Blue Mimetics Are Inhibitors of Pyruvate Kinases and Bind to the Adenosine SiteSuramin and the suramin analogue NF307 discriminate among calmodulin-binding sitesUntargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma bruceiAntipurinergic therapy corrects the autism-like features in the poly(IC) mouse modelEfficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical TrialAntipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.Sphingosine 1-phosphate evokes calcium signals in C2C12 myoblasts via Edg3 and Edg5 receptors.Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways.Nomenclature and classification of purinoceptors.Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension.Nucleotide signalling during inflammationInhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin.Proteoglycans act as cellular hepatitis delta virus attachment receptors.Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors.The P(2)-purinoceptor antagonist suramin is a competitive antagonist at vasoactive intestinal peptide receptors in the rat gastric fundus.Central nervous system agents for ischemic stroke: neuroprotection mechanismsSmall organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain.TNF superfamily protein-protein interactions: feasibility of small- molecule modulationConcomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of Trypanosoma cruziSirtuin modulators.Suramin decreases injury and improves regeneration of ethanol-induced steatotic partial liver graftsHuman African trypanosomiasis: pharmacological re-engagement with a neglected disease.Cutting off the power: inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling?Parasite neuropeptide biology: Seeding rational drug target selection?Sphingosine-1-phosphate receptor signalling in the heart.Targeting sphingosine-1-phosphate receptors in cancer.A critical look at the function of the P2Y11 receptor.The animal trypanosomiases and their chemotherapy: a reviewSuppression of cell membrane permeability by suramin: involvement of its inhibitory actions on connexin 43 hemichannels.Novel consequences of voltage-dependence to G-protein-coupled P2Y1 receptors.Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors.The binding characteristics of a human bladder recombinant P2X purinoceptor, labelled with [3H]-alpha beta meATP, [35S]-ATP gamma S or [33P]-ATPIdentification of specific inhibitors for a trypanosomatid RNA editing reaction.
P2860
Q24596889-BA80B25A-F305-4B65-BAD3-6655C9049B37Q24676296-B7F10647-1F23-4E04-AEDB-2E637DBC8B77Q26739665-6847418B-F784-4AA1-B91D-46FE92EAC1DFQ26864413-E11CA31D-BF05-4EF2-8F93-DEFF2295495DQ27667288-7310FB71-7AB0-493E-80B9-1E012F682729Q27670703-F06FE9F6-5F04-46E2-8EAE-A92FA4F470D3Q28363271-72F2E7D5-BB87-4135-99FD-98FBD9B59FBFQ28483069-04665384-AC87-4901-8910-38273D5F7706Q28487975-5F04DCA6-4F3C-453C-9314-35F24D72748AQ28550204-32E774B8-95CE-4FEF-B3C6-7656211398A6Q30418368-8D656748-B1D2-491D-9326-2257CD94AFDFQ30582584-35383913-E2AD-4699-B733-DBEABE62C5CBQ30815400-DB196B09-05F0-44BF-AD0C-12DFA4EC9786Q33749872-F920DBEE-B864-4FBA-82F1-04AA9B2B9019Q33980976-62B3EC61-40E6-46E8-BD54-82EECC41CF87Q34324355-6DEAD8EA-E941-41D9-8D02-0525BD4982B7Q34336698-7BDE5025-FFBE-4E48-B4C2-75BA17EDCC79Q34464511-1D0AAB24-02D2-4303-9BFD-31531BA9F8F1Q34597759-3C04D34B-4EC9-4696-AF83-A01E74ABE57EQ34625734-73A8A385-55BA-4BBE-804D-5F2A9A3E3332Q34792562-D50FAA73-11FD-4BE4-AE02-AC18D09E500BQ35042552-2B2245E5-FD1E-458B-8A03-3C3D391B7D06Q35137635-B414BDFB-F9DF-4834-8238-B6F3A139E34FQ35189552-612D9DBC-DA5D-430A-8A9B-313EF157236DQ35534271-7EF10901-F248-4586-9B18-68CFDEDE3BD7Q36075925-ED8A1DC4-324B-4218-8059-BF1CC66B62B3Q36165220-28D0F489-EF03-4109-B1F2-1D2B8C22EF2BQ36573237-1C4604EF-DB61-4F4C-BE2A-32DF16C94288Q36740553-B32A3A2E-5B0A-47FB-A207-FCA0767997D9Q37256412-B28E6C98-0C0E-4AC7-B616-E1D28DC3D150Q37390597-A07BC734-A59D-4B65-9A30-955790FF68C0Q37413862-A3592858-7AB6-44D1-88FC-D7AE34D17180Q37894772-DFB2E912-D92A-4920-A042-AFE555171367Q38849452-A4A7FC68-B1E0-4E7B-8487-BFA31427A30EQ38975883-D7CFD871-53AA-4349-AD1B-450FD5654704Q39014384-6064F28B-3AEE-4723-8008-8DFD582F6463Q39572678-8AF144E2-A617-49A4-B5EE-7CC33DDEC60FQ40764152-2BFA4EF3-AEE7-473A-B107-A32268924CD6Q41219782-B7A19A1C-D5F9-42C4-BBDF-778A369F2173Q41335243-038E0441-5FAB-477D-A003-2A41A89A2586
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Recent research on the biological activity of suramin.
@en
type
label
Recent research on the biological activity of suramin.
@en
prefLabel
Recent research on the biological activity of suramin.
@en
P2093
P1476
Recent research on the biological activity of suramin.
@en
P2093
Janssen LH
Vansterkenburg EL
P304
P577
1993-06-01T00:00:00Z